Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients

Table 2 Clinical characteristics of patients after liver transplantation

	Everolimus patients(n = 30)	CNI patients(n = 30)	P value
Age	60 (49-64.5)	54 (46.5- 60.5)	0.756
BMI (kg/m2)	26.2 (23.3-28.2)	27.9 (25.2-31.3)	0.211
Dyslipemia	10 (33.3)	12 (40)	0.789
Diabetes mellitus	9 (30)	13 (43.3)	0.284
HTA	18 (60)	18 (60)	1.000
Neoplasia
HCC	8 (26.7)	1 (3.3)	0.026
Solid non-hepatic neoplasia	2 (6.7)	0
Skin neoplasia	4 (13.3)	1 (3.3)
Hematological neoplasia	2 (6.7)	0
Recurrent HCV	11 (36.7)	10 (33.3)	1.000
AST (IU/L)	23 (18-53)	35 (25-66)	0.081
ALT (IU/L)	43 (18- 65)	24 (18-62)	0.260
Bilirubin (mg/dL)	0.5 (0.37-0.7)	0.85 (0.5–1.1)	0.002
Cholesterol (mg/dL)	188.5 (167-220.75)	158 (141.25-178.25)	0.002
Acute rejection	7 (23.3)	9 (30)	0.771
Chronic rejection	2 (6.7)	1 (3.3)	1.000
Biliary complications	10 (33.3)	12 (40)	0.789
APRI	0.74 (0.48-2)	0.47 (0.34-1.4)	0.135
Liver stiffness (kPa)	7.6 (5.1-8.6)	8.4 (5.6-10.7)	0.134
Concomitant steroids	6 (20)	6 (20)	1.000
Concomitant	1 (3.3)	8 (26.7)	0.026
Mycophenolate mofetil

Categorical variables are expressed as absolute n (%), continuous variables are expressed as medians and interquartillic range. HCV: Hepatitis C virus; HBV: Hepatitis B virus; LT: Liver transplantation; HCC: Hepatocarcinoma; HTA: Arterial hypertension; APRI: APRI score.